Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral administration. 1980

T Ishizaki, and T Sasaki, and T Suganuma, and Y Horai, and K Chiba, and M Watanabe, and W Asuke, and H Hoshi

The pharmacokinetics of ketoprofen was studied in the same healthy subjects after single oral, intramuscular and rectal doses, and after repeated oral administration. No significant difference in the mean t1/2 (1.13-1.27 h) was observed after the different modes of administration. The mean [AUC] 0 infinity after rectal administration of a suppository showed the minimum significant difference (p < 0.05) from that after oral administration of the capsule. The apparent volume of distribution (Vd/F) was approximately 10-15% of body weight. The renal contribution (mean, 0.10-0.15 ml/min/kg) to the plasma clearance of free ketoprofen was assumed to be, at most, 8.3-12.9%. The projected cumulative excretion of total (free plus conjugated) ketoprofen via urine exceeded 63-75% of the dose, of which approximately 90% was ketoprofen glucuronide. A mean of 71-96% and 73-93% of the oral capsule was estimated to be systemically available after administration of the intramuscular preparation and rectal suppository, respectively. In four of seven subjects, CPK concentration was elevated after the intramuscular injection. The mean steady-state concentration of ketoprofen in plasma ranged from 0.43 to 5.62 microgram/ml after the final dose of a 50 mg q. i. d. regimen. The disposition data and plasma levels observed at steady-state were in agreement with those predicted from the single oral dose study. The accumulation ratio was 1.08 +/- 0.08. The results suggest that the rectal suppository can be recommended as an extravascular mode of administration of this drug.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007660 Ketoprofen An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis. Benzoylhydratropic Acid,19,583 RP,2-(3-Benzoylphenyl)propionic Acid,Alrheumat,Alrheumum,Orudis,Profenid,RP-19583,RP 19583,RP, 19,583,RP19583
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D010666 Phenylpropionates Derivatives of 3-phenylpropionic acid, including its salts and esters.
D012007 Rectum The distal segment of the LARGE INTESTINE, between the SIGMOID COLON and the ANAL CANAL. Rectums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

T Ishizaki, and T Sasaki, and T Suganuma, and Y Horai, and K Chiba, and M Watanabe, and W Asuke, and H Hoshi
November 2001, European journal of clinical pharmacology,
T Ishizaki, and T Sasaki, and T Suganuma, and Y Horai, and K Chiba, and M Watanabe, and W Asuke, and H Hoshi
April 1998, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
T Ishizaki, and T Sasaki, and T Suganuma, and Y Horai, and K Chiba, and M Watanabe, and W Asuke, and H Hoshi
January 1994, Chirality,
T Ishizaki, and T Sasaki, and T Suganuma, and Y Horai, and K Chiba, and M Watanabe, and W Asuke, and H Hoshi
November 1990, The Journal of pharmacy and pharmacology,
T Ishizaki, and T Sasaki, and T Suganuma, and Y Horai, and K Chiba, and M Watanabe, and W Asuke, and H Hoshi
July 1989, Arzneimittel-Forschung,
T Ishizaki, and T Sasaki, and T Suganuma, and Y Horai, and K Chiba, and M Watanabe, and W Asuke, and H Hoshi
January 1986, British journal of clinical pharmacology,
T Ishizaki, and T Sasaki, and T Suganuma, and Y Horai, and K Chiba, and M Watanabe, and W Asuke, and H Hoshi
December 2000, European journal of clinical pharmacology,
T Ishizaki, and T Sasaki, and T Suganuma, and Y Horai, and K Chiba, and M Watanabe, and W Asuke, and H Hoshi
June 1993, Journal of clinical pharmacology,
T Ishizaki, and T Sasaki, and T Suganuma, and Y Horai, and K Chiba, and M Watanabe, and W Asuke, and H Hoshi
January 1979, Journal of clinical pharmacology,
T Ishizaki, and T Sasaki, and T Suganuma, and Y Horai, and K Chiba, and M Watanabe, and W Asuke, and H Hoshi
January 1982, European journal of clinical pharmacology,
Copied contents to your clipboard!